Research

You are here

ISEBIO is a multicentric, retrospective pan-European cohort that aims to develop novel stratification tools utilizing gene expression profiles and genetic alterations, with also the ultimate goal of standardizing care across Europe. By improving our understanding of disease progression, we hope that ISEBIO could lead to a unique strategy to prevent malignant transformation and provide innovative therapeutic strategies for both pre-malignant and malignant stages.

While the number of patients to be included is limited, a minimum of five hundred patient is envisioned. Priority is given to INTERCEPTOR partners opened upon request.

Main contacts of the study: 

Coordinating investigator: Prof. Pierre Saintigny (pierre.saintigny@lyon.unicancer.fr)

Project Manager : Marine Benaïssa (marine.benaissa@lyon.unicancer.fr)

Related documents: 

Keep up with the latest news,
subscribe our Newsletter

linkedin

linkedin   x  

Project information

INTERCEPTOR aims to address the challenge of generating innovative and actionable pathways by engaging with the ‘critical practice’ dimensions of transformation.

A ‘critical practice’ approach explores transformation processes in practice across different dimensions which include research, policy, business, community and individual practices.

Action Contacts

Prof. Pierre Saintigny
Action Chair
+33(0)4 69 85 60 97
pierre.saintigny@lyon.unicancer.fr

Prof. Senada Koljenovic
Action Vice Chair
+31652090524
senada.koljenovic@uza.be

COST Contacts

Dr Rosella Magli
Science Officer
+3225333833
Rossella.Magli@cost.eu

Ms Carmencita Malimban
Administrative Officer
+3225333842
carmencita.malimban@cost.eu

COST    EN FUNDED

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. www.cost.eu